Business context and reporting period
The supplied filing is Aziyo Biologics, Inc. (Nasdaq: AZYO), a regenerative-medicine company—not Elutia Inc. It is a Form 10-Q for the quarter and nine months ended September 30, 2022, filed November 14, 2022. The company sells core products for implantable-device, cardiovascular, orthopedic/spinal and soft-tissue applications, as well as non-core contract-manufactured tissue products.
Financial performance and position
Amounts below are in millions of dollars except per-share data. The financial statements are unaudited.
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Net sales | $12.4 | $11.5 | $36.5 | $36.5 |
| Gross profit | $5.0 | $3.7 | $14.2 | $15.6 |
| GAAP gross margin | 40.8% | 32.1% | 39.0% | 42.8% |
| Operating loss | $(7.8) | $(7.0) | $(22.9) | $(15.3) |
| Net loss | $(9.9) | $(8.3) | $(27.5) | $(15.8) |
| Net loss per share, basic and diluted | $(0.73) | $(0.81) | $(2.02) | $(1.54) |
- Q3 revenue increased 7.9%; core-product sales rose 4.2% and non-core sales 18.7%. Nine-month revenue was essentially unchanged: core sales fell 10.6%, largely because Medtronic stopped buying recalled FiberCel, while non-core sales rose 42.2%.
- Q3 GAAP gross margin improved, which management attributed mainly to production efficiencies and inventory management. Nine-month margin declined, primarily from product mix; management’s non-GAAP margin excluding acquired-intangible amortization was 45.9%, versus 49.8% a year earlier.
- Cash used in operations was $16.2 million for the first nine months, compared with $9.1 million in 2021. Investing used $0.4 million and financing used $5.7 million. Cash declined $22.3 million to $8.1 million from year-end 2021.
- At September 30, cash was $8.1 million; current assets were $43.7 million and current liabilities $40.2 million. Total liabilities were $71.7 million, including $20.0 million of long-term debt and a $17.6 million FiberCel litigation liability. Stockholders’ deficit was $10.7 million, versus equity of $13.5 million at December 31, 2021.
Material changes versus the prior comparable period
- Q3 sales growth and better gross margin were outweighed by higher expenses: operating expenses increased 20.4% to $12.8 million. G&A rose 27.6%, including corporate legal and CEO-transition costs; FiberCel litigation costs increased to $1.5 million from $0.1 million.
- Nine-month operating expenses rose 20.1% to $37.1 million, contributing to a larger operating and net loss. The prior-year period benefited from approximately $3.0 million of PPP-loan forgiveness and $0.55 million received in a KeraLink settlement; 2022 included debt-refinancing costs.
- Core-product sales declined year to date, including the loss of $4.9 million of FiberCel sales to Medtronic in the 2021 comparable period. Growth in contract manufacturing and other non-core products offset that decline.
Outlook, risks and unusual items
- Going concern and funding: Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements. It reported ongoing losses and cash outflows and said available cash, expected sales and potential financing may not cover operating needs and obligations. Potential responses include equity or debt financing, restructuring the Ligand revenue-interest obligation, or asset sales/licensing; none is assured.
- Debt: In August 2022, the company refinanced with a senior secured SWK term facility: $21 million drawn, with another $4 million available if specified metrics are met by September 30, 2023. The facility bears variable SOFR-based interest (weighted-average rate 11.7% through September 30), is secured by company assets, and matures August 10, 2027. Amortization is scheduled to begin in November 2024, subject to terms. A separate revolving facility of up to $8 million had not been established at quarter-end. The company reported covenant compliance at September 30.
- Liquidity covenant update: After quarter-end, the company amended the SWK agreement to extend the date for a higher minimum-liquidity requirement to November 21, 2022. Thereafter, the minimum is the greater of $5 million or the defined operating burn for the prior two consecutive quarters.
- Ligand obligation: Requires 5% of specified product sales, subject to annual minimum payments of $2.75 million, plus potential $5 million milestone payments at cumulative sales thresholds. Management forecast the first $5 million milestone payment would become payable in mid-2023.
- FiberCel recall and litigation: Following the 2021 recall of one FiberCel lot, the filing described 55 lawsuits and 42 additional claims. At September 30, the company recorded a $17.6 million estimated liability and $17.2 million of related insurance, indemnity and contribution receivables; it pursued at least $3.8 million more in potential recoveries, which was not recorded. The company said losses beyond the recorded amount were possible but could not be estimated. Twenty-four cases had been settled or were being finalized for approximately $7.2 million; one had been paid by quarter-end. Actual outcomes and recoveries remain uncertain.
- Product and commercial outlook: The 510(k) submission for CanGaroo RM Antibacterial Envelope was under FDA review. Management anticipated responding to outstanding FDA questions in time for expected clearance in Q1 2023; this is not a guarantee of approval. The company was considering strategic transactions across its business units, including partnerships and divestitures, but gave no assurance any would be completed.
- Other risks and items: Management cited procedure cancellations and access disruptions related to COVID-19, reliance on commercial partners and limited suppliers, and uncertain ability to achieve profitability. The filing reports historical seasonality, typically stronger Q4 sales, but provides no formal revenue or earnings guidance.
Important facts for investors to verify
- Confirm the filing entity: the provided text identifies Aziyo Biologics, Inc. (AZYO), despite the request metadata naming Elutia Inc.
- Assess cash runway and funding needs against the going-concern disclosure, cash balance, operating cash use, SWK liquidity covenant and potential access to additional financing.
- Track FiberCel settlement agreements, the recorded liability, unrecorded possible excess losses, and the collectability and timing of litigation-related recoveries.
- Review SWK loan economics and conditions, including variable interest, the additional $4 million draw, covenant thresholds, and the Ligand obligation and anticipated milestone.
- Monitor CanGaroo RM’s FDA review and any strategic transactions; the filing’s anticipated timing and transaction possibilities remain uncertain.